search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Drug Development


Given the clear unmet patient need and the


potential for rezafungin, Mundipharma entered into a strategic partnership in September 2019 to develop and commercialise intravenous rezafungin for the treatment and prevention of invasive fungal infections in all markets outside of the US and Japan. Our intention is to use our structured approach to development, global reach and knowl- edge of haematology/oncology to fully leverage the clinical and commercial potential of rezafungin, which has already shown promise in the STRIVE Phase II trial. The Mundipharma research team will be work-


ing closely with Cidara on the ongoing global Phase III trials for the treatment and prevention of fungal infections – supporting these both financial- ly and with our knowledge and experience. As with all the best pharmaceutical partnerships,


the potential to improve the lives of patients is clear and both companies are committed to mak- ing a difference in this area of major unmet medi- cal need.


Drug Discovery World Winter 2019/20


Improving access to medicines Alongside the benefits to drug development offered by working in partnerships, the Mundipharma model also affords the potential to improve patient access to existing medications through expanded territorial coverage. A successful example of this has been our partner-


ship with Janssen Pharmaceutica NV on the Type 2 diabetes treatment Invokana® (canagliflozin), an SGLT2 inhibitor. Diabetes is a global epidemic with significant morbidity and mortality. Thanks to our partnership with Janssen we have been able to help to increase patient access to this innovative class of Type 2 diabetes medication by marketing it in sever- al European countries. Alongside the education and engagement of healthcare professionals, we have been able to make canagliflozin available to approx- imately 200,000 European patients. Biosimilars have also been a key focus for us in


recent years, and we excelled as a provider of high- quality biosimilars in the fields of haematology, oncology, rheumatology and gastroenterology,


55


Truxima® is a rituximab biosimilar treatment to Roche’s MabThera® which is used to treat patients for follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, severe rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and moderate to severe pemphigus vulgaris


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68